-+ 0.00%
-+ 0.00%
-+ 0.00%

Amneal, Adalvo win FDA review acceptance for generic tirzepatide autoinjector ANDAs

PUBT·07/08/2026 20:14:40
Listen to the news
Amneal, Adalvo win FDA review acceptance for generic tirzepatide autoinjector ANDAs
  • Amneal, partner Adalvo won FDA acceptance for review of two ANDAs for generic tirzepatide autoinjector pens referencing Mounjaro, Zepbound.
  • Filings seek approval for single-dose prefilled pens across current indications, including type 2 diabetes, chronic weight management.
  • Amneal will lead US commercialization if cleared; IQVIA data cited U.S. tirzepatide sales rising to USD 72.8 billion in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.